Clinical trial · Observational
AIO-BNHO Comprehensive Clinico-genomics Database Network - AIO-BNHO CONNECT
NCT05701150CI-TRIAL-00086060CONNECTrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
National, retro- and prospective, observational, multicenter clinical research platform to connect clinical and genomic data of patients with advanced (locally advanced, inoperable, or metastatic) solid tumors (excluding NSCLC, SCLC, and mesothelioma) with results from multi-gene next-generation sequencing (NGS) panels (\>30 genes)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Extended documentation | Other | — | UNRESOLVED |
| Minimal documentation | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- MIN Data Set
- description
- Patients who did not receive a targeted therapy based on NGS results (outside of a clinical trial)
- interventionNames
- Other: Minimal documentation
- Other: Extended documentation
- label
- EXT Data Set
- description
- Patients who received a targeted therapy based on NGS results (outside of a clinical trial)
- interventionNames
- Other: Extended documentation
Primary outcomes (8)
- measure
- Molecular tumorboard utilization
- timeFrame
- 3 years
- description
- Proportion of patients who's case was discussed in a Molecular tumorboard
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of advanced (i.e., locally advanced, inoperable, or metastatic) solid tumor, ineligible for curative surgery and/or curative systemic therapy * Available results of commercial or non-commercial RNA- and/or DNA-based multi-gene NGS panels with \>30 genes analyzed; for non-commercial panels a list of all tested genes and multiple gene biomarkers (e.g., tumor mutational burden (TMB), microsatellite status) must be provided * Age ≥ 18 years * Signed and dated informed consent form (not applicable for inclusion of deceased patients) Exclusion Criteria: * Diagnosis of NSCLC/SCLC (C34) or mesothelioma (C45) * NGS results older than two years at the date of patient inclusion
References
Publications (0)
Data not yet available
No reference posted for this study.